# A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303

> **NCT02193217** · PHASE1 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 81 (actual)

## Conditions studied

- Relapsing-remitting Multiple Sclerosis

## Interventions

- **DRUG:** MT-1303-Low
- **DRUG:** MT-1303-High
- **DRUG:** Fingolimod
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02193217
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** 2014-12
- **Final completion:** 2015-01
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2015-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02193217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02193217, "A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02193217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*